Eli Lilly's next-generation obesity treatment "retatrutide" has ignited competition for next-generation obesity drugs, confirming a weight loss effect of up to 28% in phase 3 clinical trials
Storage requirements vary by product once removed from refrigeration
The official manufacturer of Ozempic is Novo Nordisk, a global pharmaceutical company based in Denmark
Two Houston locations in The Heights and Vintage Park
Expected milestones during therapy: Baseline assessment and initial labs Early symptom change (26 weeks) Objective lab improvement (612 weeks) Dose optimization and protocol refinement (3 months) Long-term maintenance or tapering plans (612 months) Expectations While most patients experience progressive symptom relief, some begin to notice changes within 2 to 6 weeks, with measurable reduction in inflammation present by 8 to 12 weeks
Key Takeaways Stopping GLP-1 medications can make maintenance harder because hunger increases, fullness signals decrease, and calorie needs drop at a lower weight